Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women

Gynecological Endocrinology

Volumn 10, Issue 6, 1996, Pages 413-420

  Prelevic, G M ^a   Bartram, C ^b   Wood, J ^a   Okolo, S ^c   Ginsburg, J ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Princess Grace Hospital   (United Kingdom)

^c NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bone density; Conjugated equine estrogen; Menopause; Tibolone; Transdermal estradiol

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; PREMPAK; TIBOLONE;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030450619     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599609023606     Document Type: Article

References (28)

1. Lindasy, R., Hart, D. M., Aitken, J. M., MacDonald, E. D., Anderson, J. B. and Clarke, A. C. (1976). Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet, 1, 1038-41
2. Christiansen, C., Christensen, M. S. and Transbol, I. (1981). Bone mass in postmenopausal women after withdrawal of oestrogen/gestogen replacement therapy. Lancet, 1, 459-61
3. Ettinger, B., Genant, H. K. and Cann, C. E. (1987). Postmenopausal bone loss is prevented by treatment with low dosage oestrogen with calcium. Ann. Intern. Med., 106, 40-55
4. Civitelli, R., Agnusdei, D., Nardi, P., Zacchci, F., Avioli, L. V. and Gennari, C. (1988). Effects of one-year treatment with oestrogens on bone mass, intestinal calcium absorption and 25-hydroxy-vitamin D-1alpha-hydroxylase reserve in postmenopausal osteoporosis. Calcif. Tissue Int., 42, 77-86
5. Lindasy, R. and Tohme, J. F. (1990). Oestrogen treatment of patients with established postmenopausal osteoporosis. Obstet. Gynaecol., 76, 290-5
6. Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D., Wilson, V. W. F. and Anderson, J. J. (1993). The efect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med., 329, 1141-6
7. Lufkin, E. G., Wahner, H. W., O'Fallon, W. M. O., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H. and Riggs, L. B. (1992). Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Int. Med., 117, 1-9
8. Kanis, J. A., Johnell, O., Gullberg, B., Allander, E., Dilsen, G., Gennari, C., Lopez Vaz, A. A., Lyritis, G. P., Mazzuoli, G., Miravet, L., Passeri, M., Cano, R. P., Rapado, A. and Ribot, C. (1992). Evidence for efficacy of drugs affecting bone metabolism in preventing hip fractures. Br. Med. J., 305, 1124-8
9. Maxim, P., Ettinger, D. and Spitalmy, G. M. (1995). Fracture protection provided by long-term estrogen treatment. Osteoporosis Int., 5, 23-9
10. Kicovic, P. M., Cortes-Prieto, J., Luisi, M., Milojevic, S. and Franchi, F. (1982). Placebo controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduction, 6, 81-9
11. Nevinny-Stickel, J. (1983). Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients. Arch. Gynaecol., 234, 27-31
12. Ginsburg, J., Prelevic, G., Butler, D. and Okolo, S. (1995). Clinical experience with tibolone (Livial®) over eight years. Maturitas, 21, 71-6
13. Lindsay, R., McKay Hart, D. and Kraszewski, A. (1980). Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br. Med. J., 1, 1207-9
14. Fogelman, I., Bessent, R. G., Smith, M. L., Hart, D. M. and Lindsay, R. (1981). Assessment of synthetic steroid (Org OD 14): effect on skeletal metabolism by 24 h whole-body retention of diphosphonate. Maturitas, 3, 266-9
15. Guesens, P., Dequeker, J., Gielen, J. and Schot, L. P. C. (1991). Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas, 13, 155-62
16. Rymer, J., Chapman, M. and Fogelman, I. (1994). Effect of tibolone on postmenopausal bone loss. Osteoporosis Int., 4, 314-19
17. Lyritis, G. P., Karpathuios, S., Basdekis, K., Grigoriou, O., Katostratas, T., Paspati, I., Stamatopoulos, T., Siampalioti, G. and Lyritis, P. G. (1995). Prevention of post-oophorectomy bone loss with tibolone, Maturitas, 22, 247-53
18. Lindsay, C. P., Shaw, R. W., Coelingh Bennink, H. J. T. and Kicovic, P. M. (1996). The effect of add-back treatment with tibolone (Livial) on patients treated with gonadotrophin-releasing hormone agonist triptorelin (Decapeptyl). Fertil. Steril., 65, 342-8
19. Pavlov, P. W., Ginsburg, J., Kicovic, P. M., van der Schaaf D. B., Prelevic, G. and Coelingh Bennink, H. J. T. (1996). Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Osteoporosis Int., in press
20. Selby, P. L. and Peacock, M. (1986). Dose-dependent response of symptoms, pituitary and bone to transdermal oestrogen in postmenopausal women. Br. Med. J., 293, 1337-9
21. Studd, J. W. W., Savvas, M., Watson, N., Garnett, T., Fogelman, I. and Cooper, D. (1990). The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am.J. Obstet. Gynecol., 163, 1474-9
22. Lindsay, R., Hart, D. M., Purdie, D., Ferguson, M. M., Clark, A. S. and Kraszewski, A. (1978). Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin. Sci. Mol. Med., 54, 193-5
23. Horowitz, M., Wishart, J. M., Need, A. G., Morris, H. A. and Nordin, C. B. E. (1993). Effects of norethisterone on bone related biochemical variables and forearm bone mineral in postmenopausal osteoporosis. Clin. Endocrinol., 39, 649-55
24. Grey, A., Cundy, T., Evans, M. and Reid, I. (1996). Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late postmenopausal women. Clin. Endocrinol., 44, 293-6
25. Evans, S. F. and Davie, M. W. (1996). Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin. Endocrinol., 44, 79-84
26. Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D. and Jackson, R. D. (1990). Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med., 323, 723-9
27. Storni, T., Thamsborg, G., Steiniche, T., Genant, H. K. and Sorensen, O. H. (1990). Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med., 322, 1265-71
28. Overgaard, K., Hansen, M. A., Jensen, S. B. and Christiansen, C. (1992). Effect of salcalcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br. Med. J., 305, 556-61